SCHEDULE 13G/A: BlackRock Discloses 7.6% Passive Stake in Boston Scientific Corp
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% passive beneficial ownership stake in Boston Scientific Corp as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 113,006,671 shares of Boston Scientific Corp common stock.
- This represents 7.6% of Boston Scientific Corp's total outstanding common stock.
- BlackRock holds sole voting power over 100,792,911 shares and sole dispositive power over 113,006,671 shares.
- The filing is an Amendment No. 13 to a Schedule 13G, indicating an update to a previously reported passive investment.
- The securities are stated to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of Boston Scientific Corp.
Sentiment
Score: 7
Explanation: The filing is neutral to positive, indicating a stable, passive investment by a major institutional holder, which generally signals confidence without implying any active strategic involvement or concerns.
Positives
- BlackRock, a major institutional investor, holds a significant passive stake, which can signal long-term confidence in Boston Scientific Corp.
- The filing confirms the shares are held in the ordinary course of business, not for control purposes, suggesting a stable investment without activist intent.
Negatives
- No specific negative information regarding Boston Scientific Corp's operations or financial performance is disclosed in this passive ownership filing.
Risks
- The filing itself does not detail operational or financial risks for Boston Scientific Corp, as it pertains solely to BlackRock's ownership stake.
Future Outlook
This filing, a Schedule 13G, pertains to passive ownership disclosure and does not contain forward-looking statements or guidance regarding Boston Scientific Corp's future outlook.
Management Comments
- Spencer Fleming, Managing Director at BlackRock, Inc., certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing reflects a routine disclosure by BlackRock, Inc., one of the world's largest asset managers, regarding its passive investment in Boston Scientific Corp, a leading global medical technology company. Such significant institutional holdings are common for large-cap companies in the healthcare sector, indicating broad market confidence.
Comparison to Industry Standards
- This Schedule 13G filing is a disclosure of beneficial ownership and does not provide financial or operational results for comparison to industry standards or specific comparable companies/projects.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Authorized Signatories for SEC Filings (BlackRock, Inc.) | Previous Power of Attorney signatories (dated April 30, 2023) | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 01/21/2025 | Update and revocation of previous Power of Attorney for compliance with ownership or control-person reporting requirements. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- No legal proceedings or regulatory matters are disclosed in this filing.
Related Party Transactions
- No related party transactions are disclosed in this filing.
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional holding, potentially reinforcing confidence in the company's stability.
- Management: Awareness of a large, passive institutional investor holding a substantial stake.
Next Steps
- The document does not outline specific future actions or milestones for Boston Scientific Corp. BlackRock, Inc. will continue to hold its passive investment in Boston Scientific Corp in the ordinary course of business.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the new Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which required the filing of this statement (ownership snapshot date). |
| 04/17/2025 | Date of signature and filing of the Schedule 13G Amendment No. 13. |
Keywords
Boston Scientific, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.